Trey Martin: Yes. Yes. Thank you. We, looking specifically at China BST, which again was a big growth driver for them in ‘21 and ‘22, really, the difference between what we’ve been talking about so far, that is that the leg down for China and PST really started in the second half of last year. And having just looked at a lot of the numbers, obviously, we are, I would say, relatively stable at this new level. So there are year-over-year comparisons from growth that are now steady that were harder for us certainly in the second half last year and first half of this year. So we see China not so far not taking any further steps down but at a relatively stable rate for the past three quarters in BST specific.
Kevin Herde: Yes. And just to put some numerical context to, in the second quarter of 2022 when we first saw this decline that Ray alluded to China was about 19.5% growth for our BST business. In the most recently predated quarter, China was 19.5% of the revenues in the BST business. And its range from 18.4%, 22.9% in those periods that I just spoke to. So it’s leveled out. We don’t have, we believe, ongoing exposure to see that go much lower than that. I think that’s the level that’s going to support the current environment that we’re seeing for biologic manufacturing in China.
Operator: Our next question comes from the line of Matthew Sykes with Goldman Sachs. Your line is open.
Unidentified Analyst: Hi, this is Ivy on for Matt. Any updates on the progress of Founders 2? And how are you thinking about bringing on additional capacity in a year where demand is being impacted by destocking, COVID rolling off and weaker farmer spend?
Kevin Herde: Yes, I’ll start. Yes, certainly, not ideal to bring online additional capacity in this year, but these are decisions you make at least 2 years in advance just given the length to take some of these facilities. And frankly, it’s still necessary, and we still think it was the right decision to have redundancy for our manufacturing of CleanCap. Flanders 1 accomplish that and obviously, it was funded through our [indiscernible] brand, Flanders 2, again, a big part of our commercial strategy, and I’ll let the others in the room comment on that, but that’s certainly something that we’re not rushing to finish, obviously, given the demand, but it is certainly something that in the context of commercial discussions is an incredibly important asset that we need to have is, frankly, table stakes to be a competitor in the Nucleic Acid Solutions part of our business.
Trey Martin: Yes. So Flanders 2 specifically is where the mRNA services happen at Phase 2 and beyond we have our existing G&P services for chemistry and [indiscernible] RNA, all in the Wateridge Facility that there is a nice picture of on our [indiscernible]. So as we talk through customer program progression, we have the ability to turn that on at the right time for the right customers. And obviously, with all the work we’ve done this quarter rightsizing and realigning our operations footprint, we have not proactively leaned into Flanders 2, until we have solid bookings schedule. And Becky can probably just add a few comments because that’s been our primary focus here this last quarter.
Becky Buzzeo: Yes, sure. I mean, look, we’re incredibly excited about the Flanders 2 building. And I think that you’re always going to be building ahead when you’re offering more of that GMP manufacturing facility footprint. We have a number of customers that have come through our research use only manufacturing services, they then progress to file an IND, and we’ve made that GMP material for them, and now they have interest and they are going in to Phase 2 and then sometimes it’s the Phase 2/3 combo. And so in those cases, where it lines up that we’re going to be GMP-ready mid-next year, those are the customers that we’re engaging with that are on that same pathway to need that clinical material for Phase 2 or a Phase 2/3 combo. And so we continue to progress that. And I think that’s a definitely a great development in our ability to continue to service customers and be best in making CleanCap mRNA, which is what is really what we do well.
